scholarly journals A Novel Mutation in the V2 Vasopressin Receptor Gene in Two Siblings with Nephrogenic Diabetes Insipidus

1995 ◽  
Vol 4 (1) ◽  
pp. 33-37
Author(s):  
Toshihiro Tajima ◽  
Jun Nakae ◽  
Mari Murashita ◽  
Nozomi Shinohara ◽  
Kenji Yuri ◽  
...  
1994 ◽  
Vol 3 (8) ◽  
pp. 1429-1430 ◽  
Author(s):  
David Wenkert ◽  
John J. Merendino ◽  
Andrew Shenker ◽  
Nina Thambl ◽  
Gary L. Robertson ◽  
...  

1992 ◽  
Vol 2 (2) ◽  
pp. 103-106 ◽  
Author(s):  
Yang Pan ◽  
Aida Metzenberg ◽  
Soma Das ◽  
Biqi Jing ◽  
Jane Gitschier

2017 ◽  
Vol 07 (01) ◽  
pp. e1-e3
Author(s):  
Abdulsalam Abu-Libdeh ◽  
Isaiah Wexler ◽  
Imad Dweikat ◽  
David Zangen ◽  
Bassam Abu-Libdeh

AbstractNephrogenic diabetes insipidus (NDI) is a urinary concentrating defect resulting from resistance of the collecting duct to the antidiuretic action of vasopressin (AVP). The X-linked recessive form is the most frequent genetic cause of inherited NDI and can be caused by mutations in the gene encoding the V2 vasopressin receptor (AVPR2). A Palestinian male infant presented in the neonatal period with failure to thrive, vomiting, irritability, fever, and polyuria, and had biochemical findings consistent with NDI. The diagnosis of NDI was established based on the clinical picture, absent response to desmopressin, and a similarly affected elder brother. Sequencing of the AVPR2 gene for the patient and his affected brother revealed a novel missense mutation with replacement of G by A in codon 82 located in exon 2 (TGC → TAC), causing a cysteine to tyrosine substitution (C82Y). Testing of the mother showed that she was the carrier of that mutation. This is the identified AVPR2 mutation in a Palestinian family. Knowledge of these mutations will allow genetic counseling and early diagnosis of affected males.


2011 ◽  
Vol 287 (3) ◽  
pp. 2099-2106 ◽  
Author(s):  
Kazuhiro Takahashi ◽  
Noriko Makita ◽  
Katsunori Manaka ◽  
Masataka Hisano ◽  
Yuko Akioka ◽  
...  

2004 ◽  
Vol 18 (8) ◽  
pp. 2074-2084 ◽  
Author(s):  
Virginie Bernier ◽  
Monique Lagacé ◽  
Michèle Lonergan ◽  
Marie-Françoise Arthus ◽  
Daniel G. Bichet ◽  
...  

Abstract In most cases, nephrogenic diabetes insipidus results from mutations in the V2 vasopressin receptor (V2R) gene that cause intracellular retention of improperly folded receptors. We previously reported that cell permeable V2R antagonists act as pharmacological chaperones that rescue folding, trafficking, and function of several V2R mutants. More recently, the vasopressin antagonist, SR49059, was found to be therapeutically active in nephrogenic diabetes insipidus patients. Three of the patients with positive responses harbored the mutation R137H, previously reported to lead to constitutive endocytosis. This raises the possibility that, instead of acting as a pharmacological chaperone by favoring proper maturation of the receptors, SR49059 could mediate its action on R137H V2R by preventing its endocytosis. Here we report that the β-arrestin-mediated constitutive endocytosis of R137H V2R is not affected by SR49059, indicating that the functional rescue observed does not result from a stabilization of the receptor at the cell surface. Moreover, metabolic labeling revealed that R137H V2R is also poorly processed to the mature form. SR49059 treatment significantly improved its maturation and cell surface targeting, indicating that the functional rescue of R137H V2Rs results from the pharmacological chaperone action of the antagonist.


Sign in / Sign up

Export Citation Format

Share Document